Plus therapeutics announces fda clearance of investigational new drug application for 186rnl for the treatment of leptomeningeal metastases

Patient accrual for the phase 1 dose escalation clinical trial of 186 rnl (respect-lm) is expected in the fourth quarter of 2021

PSTV Ratings Summary

PSTV Quant Ranking